SCHEMBL17927373

SCHEMBL17927373

CCc1ccc(/C=C2\SC(=O)N(CCNC(=O)c3cccc(O)c3O)C2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 5/20 0.60
▸ MAPT P10636 8/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ PKM P14618 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ POLB P06746 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ MITF O75030 1/20 0.51
▸ LMNA P02545 4/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ MAX P61244 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ MAPK1 P28482 3/20 0.49
▸ SAE1 Q9UBE0 1/20 0.49
▸ UBA2 Q9UBT2 1/20 0.49
▸ NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17927375 1.00 MYC (0.60) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927391 0.91 MYC (0.54) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927394 0.91 MYC (0.54) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927336 0.83 MYC (0.60) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927338 0.83 MYC (0.60) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927296 0.82 MYC (0.70) MYCMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL17927295 0.82 MYC (0.70) MYCMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL17934485 0.81 MYC (0.55) MYCMAXMAPK1KDR
SCHEMBL17927353 0.80 MYC (0.56) MYCMAPTSMN1; SMN2PKMALDH1A1
SCHEMBL17927352 0.80 MYC (0.56) MYCMAPTSMN1; SMN2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016115360-A1 C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2016-07-21 — — WO claimed
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 — — US disclosed
WO-2016115360-A1 C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2016-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM XIAP, CUL4A, CUL1 MYC 226/4885MAPT 3111/4885SMN1; SMN2 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback